A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of Psychosis [clinicaltrials:NCT00644800]

Bio2RDF uri

A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of Psychosis [clinicaltrials:NCT00644800]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT00644800

Bio2RDF identifier

NCT00644800

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00644800

http://www.w3.org/2001/XMLSchema#string

brief summary [clinicaltrials_vocabulary:brief-summary]

To assess the efficacy, ...... lusional disorder and others.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

A Study of the Efficacy and Sa ...... for the Treatment of Psychosis

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Change from baseline in Positive and Negative Syndrome Scale (PANSS) excitation items scores Days 1-3 (end of intramuscular dosing) [clinicaltrials_resource:59fc4560bf027dac0c1a0e3bef332ff3]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Change from baseline in Positive and Negative Syndrome Scale (PANSS) excitation items scores Days 1-3 (end of intramuscular dosing) [clinicaltrials_resource:184b03f0f2e6c67b73758fb4b66c8e63]

Change from baseline in Positive and Negative Syndrome Scale (PANSS) excitation items scores Days 1-3 (end of intramuscular dosing) [clinicaltrials_resource:2fc3b7697edcfc5acf1bf2134450f524]

Change from baseline in Positive and Negative Syndrome Scale (PANSS) excitation items scores Days 1-3 (end of intramuscular dosing) [clinicaltrials_resource:84d4735ee2715e0a1ef0c988319831b5]

Change from baseline in Positive and Negative Syndrome Scale (PANSS) excitation items scores Days 1-3 (end of intramuscular dosing) [clinicaltrials_resource:984b65f3c031d2664b39aac670db2948]

Change from baseline in Positive and Negative Syndrome Scale (PANSS) excitation items scores Days 1-3 (end of intramuscular dosing) [clinicaltrials_resource:9e526d35e710ec7ec1f51784de08f0e1]

Change from baseline in Positive and Negative Syndrome Scale (PANSS) excitation items scores Days 1-3 (end of intramuscular dosing) [clinicaltrials_resource:aa4ea3206bdcff8ef860570139012f89]

Change from baseline in Positive and Negative Syndrome Scale (PANSS) excitation items scores Days 1-3 (end of intramuscular dosing) [clinicaltrials_resource:b2145bae62543269a322904ffe228021]

Change from baseline in Positive and Negative Syndrome Scale (PANSS) excitation items scores Days 1-3 (end of intramuscular dosing) [clinicaltrials_resource:d4aa85304821eedd382cc99f1eecac20]

completion date [clinicaltrials_vocabulary:completion-date]

2004-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

condition [clinicaltrials_vocabulary:condition]

Mania [clinicaltrials_resource:0ce3f285aced0406fbabccda74b24aa5]

Acute Exacerbation of Psychosis [clinicaltrials_resource:1abd1d25c3a53154191cc79e4686b9ae]

Delusional Disorder [clinicaltrials_resource:39df4a6d37640f094ac68f6cf65d01d7]

Schizophrenia [clinicaltrials_resource:79ce9bd96a3184b1ee7c700aa2927e67]

condition browse [clinicaltrials_vocabulary:condition-browse]

Mental Disorders [clinicaltrials_resource:c4384b035f00ca3b7e970fa0fe14c69b]

Psychotic Disorders [clinicaltrials_resource:d5e4cc62050b3a2ba428e3e64296c90a]

condition mesh [clinicaltrials_vocabulary:condition-mesh]

Mental Disorders [clinicaltrials_resource:c4384b035f00ca3b7e970fa0fe14c69b]

Psychotic Disorders [clinicaltrials_resource:d5e4cc62050b3a2ba428e3e64296c90a]

country [clinicaltrials_vocabulary:country]

Brazil [clinicaltrials_resource:42537f0fb56e31e20ab9c2305752087d]

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00644800 [clinicaltrials_resource:99eb6bcbf0344c416510fb17ed732d14]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2008-03-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Ziprasidone [clinicaltrials_resource:684d81d8cc68a297a20ef43a10aee001]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Ziprasidone [clinicaltrials_resource:5ba53562011eed9de8f345cd366a6ae0]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

Yes

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2008-04-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Pfizer [clinicaltrials_resource:c1b9f1c2d5cc1361ccf28b0108bd7179]

link [clinicaltrials_vocabulary:link]

To obtain contact information for a study center near you, click here. [clinicaltrials_resource:7531fbcbd9d12e466ed7826738ba2db2]

location [clinicaltrials_vocabulary:location]

Pfizer Investigational Site [clinicaltrials_resource:42fc3dd78c67d9141680f1e990361821]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00644800

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

An Open, Multicenter, Non-Comp ...... Patients With Acute Psychosis

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

A1281074

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Pfizer CT.gov Call Center [clinicaltrials_resource:7340297fe8931ae620f630868e86174a]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

Brazil: National Health Surveillance Agency [clinicaltrials_resource:3fd0898bfb965be46dbcf10b0da5ce8a]

phase [clinicaltrials_vocabulary:phase]

Phase 4 [clinicaltrials_resource:ec41833bc88cd90619c4d85c549688bd]

responsible party [clinicaltrials_vocabulary:responsible-party]

Director, Clinical Trial Disclosure Group, Pfizer, Inc. [clinicaltrials_resource:757fb3099ae972f7f7ca50809082bbc0]

source [clinicaltrials_vocabulary:source]

Pfizer [clinicaltrials_resource:c1b9f1c2d5cc1361ccf28b0108bd7179]

start date [clinicaltrials_vocabulary:start-date]

2003-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00644800 study design [clinicaltrials_resource:deec32cda6fb163105cc0b4fb83602cd]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00644800

verification date [clinicaltrials_vocabulary:verification-date]

2008-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00644800

http://www.w3.org/2001/XMLSchema#string

title

A Study of the Efficacy and Sa ...... for the Treatment of Psychosis

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

A Study of the Efficacy and Sa ...... s [clinicaltrials:NCT00644800]

@en